Treatment of Cardiac Transthyretin Amyloidosis: An Update

Michele Emdin; Alberto Aimo; Claudio Rapezzi; Marianna Fontana; Federico Perfetto; Petar M. Seferović; Andrea Barison; Vincenzo Castiglione; Giuseppe Vergaro; Alberto Giannoni; Claudio Passino; Giampaolo Merlini


Eur Heart J. 2019;40(45):3699-3706. 

In This Article

Inhibition of Oligomer Aggregation and Oligomer Disruption

Epigallocatechin Gallate

Epigallocatechin-3-gallate (EGCG) is the most abundant catechin in green tea.[32] Epigallocatechin-3-gallate binds to soluble TTR decreasing the likelihood of tetramer dissociation, inhibits oligomer aggregation into amyloid fibres, thus promoting the disaggregation of TTR amyloid fibres.[32] In a single centre, open-label study, 30 patients with cardiac ATTR (both variant and wt) received EGCG 675 mg/day per os and were compared with 35 cardiac ATTR patients treated with HF supportive therapy alone. Over 12 months of treatment, EGCG did not improve survival and did not change echocardiographic parameters or NT-proBNP, compared with baseline.[33]